Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

Abstract

Isocitrate dehydrogenase (IDH) mutations represent pivotal oncogenic drivers across multiple malignancies. Mutant IDH enzymes acquire neomorphic activity that produces the oncometabolite D-2-hydroxyglutarate (D-2HG), which competitively inhibits α-ketoglutarate-dependent dioxygenases and promotes epigenetic reprogramming, differentiation arrest, and malignant transformation. Beyond tumor cell–intrinsic effects, D-2HG profoundly remodels the tumor immune microenvironment by directly suppressing T-cell proliferation and effector functions, silencing natural killer (NK) cell-activating ligands, and impairing dendritic cell maturation. In this review, we delineate the mechanistic basis of mutant IDH in oncogenesis and evaluate the development of selective allosteric inhibitors validated through rigorous preclinical models demonstrating potent D-2HG suppression. Clinical translation has yielded multiple FDA-approved IDH inhibitors demonstrating significant therapeutic efficacy across diverse IDH-mutant malignancies. Notably, dual inhibitors have extended progression-free survival in gliomas, whereas triple-combination regimens have achieved substantial complete remission rates in acute myeloid leukemia. However, therapeutic resistance has emerged through second-site mutations, clonal evolution, and metabolic reprogramming. We also discuss rational combinatorial strategies integrating IDH inhibitors with hypomethylating agents (HMAs), targeted therapies, and immunomodulatory approaches, alongside emerging technologies such as single-cell profiling and spatial transcriptomics. By addressing both achievements and challenges, this review underscores the translational relevance of IDH-targeted therapy and its potential to reshape precision oncology through refined patient stratification and enhanced therapeutic efficacy.

Keywords

2-hydroxyglutarate / isocitrate dehydrogenase mutation / targeted inhibitors / therapeutic resistance / tumor immune microenvironment

References

[1] D. W. Parsons, S. Jones, X. Zhang, et al., “An Integrated Genomic Analysis of Human Glioblastoma Multiforme,” Science 321, no. 5897 (2008): 1807–1812.

[2] T. J. Ley, C. Miller, L. Ding, et al., “Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia,” New England Journal of Medicine 368, no. 22 (2013): 2059–2074.

[3] G. Marcucci, T. Haferlach, and H. Döhner, “Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications,” Journal of Clinical Oncology 29, no. 5 (2011): 475–486.

[4] P. Paschka, R. F. Schlenk, V. I. Gaidzik, et al., “IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication,” Journal of Clinical Oncology 28, no. 22 (2010): 3636–3643.

[5] D. R. Borger, K. K. Tanabe, K. C. Fan, et al., “Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping,” Oncologist 17, no. 1 (2012): 72–79.

[6] M. F. Amary, K. Bacsi, F. Maggiani, et al., “IDH1 and IDH2 Mutations Are Frequent Events in Central Chondrosarcoma and Central and Periosteal Chondromas but Not in Other Mesenchymal Tumours,” Journal of Pathology 224, no. 3 (2011): 334–343.

[7] T. C. Pansuriya, R. Van Eijk, P. d'Adamo, et al., “Somatic Mosaic IDH1 and IDH2 Mutations Are Associated With Enchondroma and Spindle Cell Hemangioma in Ollier Disease and Maffucci Syndrome,” Nature Genetics 43, no. 12 (2011): 1256–1261.

[8] L. Dang, K. Yen, and E. C. Attar, “IDH Mutations in Cancer and Progress Toward Development of Targeted Therapeutics,” Annals of Oncology 27, no. 4 (2016): 599–608.

[9] L. Dang, D. W. White, S. Gross, et al., “Cancer-Associated IDH1 Mutations Produce 2-Hydroxyglutarate,” Nature 462, no. 7274 (2009): 739–744.

[10] S. Gross, R. A. Cairns, M. D. Minden, et al., “Cancer-Associated Metabolite 2-Hydroxyglutarate Accumulates in Acute Myelogenous Leukemia With Isocitrate Dehydrogenase 1 and 2 Mutations,” Journal of Experimental Medicine 207, no. 2 (2010): 339–344.

[11] M. S. Waitkus, B. H. Diplas, and H. Yan, “Biological Role and Therapeutic Potential of IDH Mutations in Cancer,” Cancer Cell 34, no. 2 (2018): 186–195.

[12] W. Xu, H. Yang, Y. Liu, et al., “Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases,” Cancer Cell 19, no. 1 (2011): 17–30.

[13] M. E. Figueroa, O. Abdel-Wahab, C. Lu, et al., “Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation,” Cancer Cell 18, no. 6 (2010): 553–567.

[14] C. Lu, P. S. Ward, G. S. Kapoor, et al., “IDH Mutation Impairs Histone Demethylation and Results in a Block to Cell Differentiation,” Nature 483, no. 7390 (2012): 474–478.

[15] R. Ma and C. H. Yun, “Crystal Structures of Pan-IDH Inhibitor AG-881 in Complex With Mutant Human IDH1 and IDH2,” Biochemical and Biophysical Research Communications 503, no. 4 (2018): 2912–2917.

[16] E. M. Stein, C. D. Dinardo, D. A. Pollyea, et al., “Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia,” Blood 130, no. 6 (2017): 722–731.

[17] S. Dhillon, “Correction to: Ivosidenib: First Global Approval,” Drugs 79, no. 1 (2019): 107.

[18] C. Kang, “Olutasidenib: First Approval,” Drugs 83, no. 4 (2023): 341–346.

[19] Y. N. Lamb, “Correction: Vorasidenib: First Approval,” Drugs 84, no. 12 (2024): 1673.

[20] M. I. De La Fuente, H. Colman, M. Rosenthal, et al., “Olutasidenib (FT-2102) in Patients With Relapsed or Refractory IDH1-Mutant Glioma: A Multicenter, Open-Label, Phase Ib/II Trial,” Neuro-Oncology 25, no. 1 (2023): 146–156.

[21] S. De Botton, C. Récher, J. Cortes, et al., “Olutasidenib Demonstrates Significant Clinical Activity in Mutated IDH1 Acute Myeloid Leukaemia Arising From a Prior Myeloproliferative Neoplasm,” British Journal of Haematology 206, no. 4 (2025): 1121–1128.

[22] J. E. Cortes, G. J. Roboz, M. R. Baer, et al., “Olutasidenib in Combination With Azacitidine Induces Durable Complete Remissions in Patients With Relapsed or Refractory mIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial,” Journal of Hematology & Oncology 18, no. 1 (2025): 7.

[23] L. Hu, X. Wei, W. Zhao, et al., “HMPL-306 in Relapsed or Refractory IDH1- and/or IDH2-Mutated Acute Myeloid Leukemia: A Phase 1 Study,” Med 6, no. 6 (2025): 100575.

[24] P. Montesinos, C. Recher, S. Vives, et al., “Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia,” New England Journal of Medicine 386, no. 16 (2022): 1519–1531.

[25] C. D. Dinardo, A. C. Schuh, E. M. Stein, et al., “Enasidenib Plus Azacitidine Versus Azacitidine Alone in Patients With Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005): A Single-Arm, Phase 1b and Randomised, Phase 2 Trial,” Lancet Oncology 22, no. 11 (2021): 1597–1608.

[26] M. Ramadas, N. Jacob, M. Ameratunga, and L. Gately, “Unlocking Therapeutic Synergy: IDH Inhibitors and Immunotherapy Combination in Preclinical and Clinical IDH Mutant Glioma Models—A Systematic Review,” Journal of Clinical Neuroscience 136 (2025): 111281.

[27] L. Bunse, S. Pusch, T. Bunse, et al., “Suppression of Antitumor T Cell Immunity by the Oncometabolite (R)-2-Hydroxyglutarate,” Nature Medicine 24, no. 8 (2018): 1192–1203.

[28] A. S. Mckenney, A. N. Lau, A. V. H. Somasundara, et al., “JAK2/IDH-Mutant-Driven Myeloproliferative Neoplasm Is Sensitive to Combined Targeted Inhibition,” Journal of Clinical Investigation 128, no. 2 (2018): 789–804.

[29] C. A. Lachowiez, S. Loghavi, Z. Zeng, et al., “A Phase Ib/II Study of Ivosidenib With Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies,” Blood Cancer Discovery 4, no. 4 (2023): 276–293.

[30] M. D. Amatangelo, L. Quek, A. Shih, et al., “Enasidenib Induces Acute Myeloid Leukemia Cell Differentiation to Promote Clinical Response,” Blood 130, no. 6 (2017): 732–741.

[31] S. Choe, H. Wang, C. D. Dinardo, et al., “Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory AML,” Blood Advances 4, no. 9 (2020): 1894–1905.

[32] A. C. H. Liu, S. Cathelin, Y. Yang, et al., “Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia Through Suppression of Stemness,” Cancer Research 82, no. 23 (2022): 4325–4339.

[33] F. Lang, K. Kaur, H. Fu, et al., “D-2-Hydroxyglutarate Impairs DNA Repair Through Epigenetic Reprogramming,” Nature Communications 16, no. 1 (2025): 1431.

[34] X. Chen and J. R. Cubillos-Ruiz, “Endoplasmic Reticulum Stress Signals in the Tumour and Its Microenvironment,” Nature Reviews Cancer 21, no. 2 (2021): 71–88.

[35] J. Downward, “Targeting RAS Signalling Pathways in Cancer Therapy,” Nature Reviews Cancer 3, no. 1 (2003): 11–22.

[36] A. Pouyan, M. Ghorbanlo, M. Eslami, et al., “Glioblastoma Multiforme: Insights Into Pathogenesis, Key Signaling Pathways, and Therapeutic Strategies,” Molecular Cancer 24, no. 1 (2025): 58.

[37] A. M. Intlekofer, A. H. Shih, B. Wang, et al., “Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations,” Nature 559, no. 7712 (2018): 125–129.

[38] J. M. Cleary, B. Rouaisnel, A. Daina, et al., “Secondary IDH1 Resistance Mutations and Oncogenic IDH2 Mutations Cause Acquired Resistance to Ivosidenib in Cholangiocarcinoma,” NPJ Precision Oncology 6, no. 1 (2022): 61.

[39] J. J. Harding, M. A. Lowery, A. H. Shih, et al., “Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition,” Cancer Discovery 8, no. 12 (2018): 1540–1547.

[40] L. Stuani, M. Sabatier, E. Saland, et al., “Mitochondrial Metabolism Supports Resistance to IDH Mutant Inhibitors in Acute Myeloid Leukemia,” Journal of Experimental Medicine 218, no. 5 (2021): e20200924.

[41] H. Yan, D. W. Parsons, G. Jin, et al., “IDH1 and IDH2 Mutations in Gliomas,” New England Journal of Medicine 360, no. 8 (2009): 765–773.

[42] H. Noushmehr, D. J. Weisenberger, K. Diefes, et al., “Identification of a CpG Island Methylator Phenotype That Defines a Distinct Subgroup of Glioma,” Cancer Cell 17, no. 5 (2010): 510–522.

[43] S. Zarnegar-Lumley, T. A. Alonzo, R. B. Gerbing, et al., “Characteristics and Prognostic Impact of IDH Mutations in AML: A COG, SWOG, and ECOG Analysis,” Blood Advances 7, no. 19 (2023): 5941–5953.

[44] A. N. Boscoe, C. Rolland, and R. K. Kelley, “Frequency and Prognostic Significance of Isocitrate Dehydrogenase 1 Mutations in Cholangiocarcinoma: A Systematic Literature Review,” Journal of Gastrointestinal Oncology 10, no. 4 (2019): 751–765.

[45] C. Lu, S. Venneti, A. Akalin, et al., “Induction of Sarcomas by Mutant IDH2,” Genes & Development 27, no. 18 (2013): 1986–1998.

[46] M. R. Kang, M. S. Kim, J. E. Oh, et al., “Mutational Analysis of IDH1 Codon 132 in Glioblastomas and Other Common Cancers,” International Journal of Cancer 125, no. 2 (2009): 353–355.

[47] I. C. Hvinden, T. Cadoux-Hudson, C. J. Schofield, and J. S. O. Mccullagh, “Metabolic Adaptations in Cancers Expressing Isocitrate Dehydrogenase Mutations,” Cell Reports Medicine 2, no. 12 (2021): 100469.

[48] C. Riobello, A. López-Hernández, V. N. Cabal, et al., “IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management,” American Journal of Surgical Pathology 44, no. 3 (2020): 396–405.

[49] S. Dogan, D. J. Chute, B. Xu, et al., “Frequent IDH2 R172 Mutations in Undifferentiated and Poorly-Differentiated Sinonasal Carcinomas,” Journal of Pathology 242, no. 4 (2017): 400–408.

[50] J. Guilmette and P. M. Sadow, “High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling,” Archives of Pathology & Laboratory Medicine 143, no. 11 (2019): 1416–1419.

[51] F. Lemonnier, R. A. Cairns, S. Inoue, et al., “The IDH2 R172K Mutation Associated With Angioimmunoblastic T-Cell Lymphoma Produces 2HG in T Cells and Impacts Lymphoid Development,” Proceedings of the National Academy of Sciences of the United States of America 113, no. 52 (2016): 15084–15089.

[52] R. A. Cairns and T. W. Mak, “Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities,” Cancer Discovery 3, no. 7 (2013): 730–741.

[53] J. P. Hemerly, A. U. Bastos, and J. M. Cerutti, “Identification of Several Novel Non-p.R132 IDH1 Variants in Thyroid Carcinomas,” European Journal of Endocrinology 163, no. 5 (2010): 747–755.

[54] A. K. Murugan, E. Bojdani, and M. Xing, “Identification and Functional Characterization of Isocitrate Dehydrogenase 1 (IDH1) Mutations in Thyroid Cancer,” Biochemical and Biophysical Research Communications 393, no. 3 (2010): 555–559.

[55] J. J. Miller, H. A. Shih, O. C. Andronesi, and D. P. Cahill, “Isocitrate Dehydrogenase-Mutant Glioma: Evolving Clinical and Therapeutic Implications,” Cancer 123, no. 23 (2017): 4535–4546.

[56] X. Xu, J. Zhao, Z. Xu, et al., “Structures of Human Cytosolic NADP-Dependent Isocitrate Dehydrogenase Reveal a Novel Self-Regulatory Mechanism of Activity,” Journal of Biological Chemistry 279, no. 32 (2004): 33946–33957.

[57] X. Chen, P. Sun, Y. Liu, S. Shen, T. Ma, and J. Ding, “Structures of a Constitutively Active Mutant of Human IDH3 Reveal New Insights Into the Mechanisms of Allosteric Activation and the Catalytic Reaction,” Journal of Biological Chemistry 298, no. 12 (2022): 102695.

[58] J. Yang, H. Zhu, T. Zhang, and J. Ding, “Structure, Substrate Specificity, and Catalytic Mechanism of Human D-2-HGDH and Insights Into Pathogenicity of Disease-Associated Mutations,” Cell Discovery 7, no. 1 (2021): 3.

[59] M. Tahiliani, K. P. Koh, Y. Shen, et al., “Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1,” Science 324, no. 5929 (2009): 930–935.

[60] S. Turcan, V. Makarov, J. Taranda, et al., “Mutant-IDH1-Dependent Chromatin State Reprogramming, Reversibility, and Persistence,” Nature Genetics 50, no. 1 (2018): 62–72.

[61] Z. Yang, B. Jiang, Y. Wang, et al., “2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter,” Cell Reports 19, no. 9 (2017): 1846–1857.

[62] S. Turcan, D. Rohle, A. Goenka, et al., “IDH1 Mutation Is Sufficient to Establish the Glioma Hypermethylator Phenotype,” Nature 483, no. 7390 (2012): 479–483.

[63] S. M. Kooistra and K. Helin, “Molecular Mechanisms and Potential Functions of Histone Demethylases,” Nature Reviews Molecular Cell Biology 13, no. 5 (2012): 297–311.

[64] R. Chowdhury, K. K. Yeoh, Y.-M. Tian, et al., “The Oncometabolite 2-Hydroxyglutarate Inhibits Histone Lysine Demethylases,” EMBO Reports 12, no. 5 (2011): 463–469.

[65] G. L. Wang and G. L. Semenza, “Purification and Characterization of Hypoxia-Inducible Factor 1,” Journal of Biological Chemistry 270, no. 3 (1995): 1230–1237.

[66] E. E. Wicks and G. L. Semenza, “Hypoxia-Inducible Factors: Cancer Progression and Clinical Translation,” Journal of Clinical Investigation 132, no. 11 (2022): e159839.

[67] M. Safran and W. G. Kaelin, “HIF Hydroxylation and the Mammalian Oxygen-Sensing Pathway,” Journal of Clinical Investigation 111, no. 6 (2003): 779–783.

[68] S. Zhao, Y. Lin, W. Xu, et al., “Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1alpha,” Science 324, no. 5924 (2009): 261–265.

[69] P. Koivunen, S. Lee, C. G. Duncan, et al., “Transformation by the (R)-enantiomer of 2-Hydroxyglutarate Linked to EGLN Activation,” Nature 483, no. 7390 (2012): 484–488.

[70] A. Dimou, V. Tsimihodimos, and E. Bairaktari, “The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology,” International Journal of Molecular Sciences 23, no. 7 (2022): 4022.

[71] S. K. Mcbrayer, J. R. Mayers, G. J. Dinatale, et al., “Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma,” Cell 175, no. 1 (2018): 101–116.e25.

[72] F. Chen, K. Bian, Q. Tang, et al., “Oncometabolites d- and l-2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes Under Physiological Conditions,” Chemical Research in Toxicology 30, no. 4 (2017): 1102–1110.

[73] B. Xu, D. Liu, Z. Wang, R. Tian, and Y. Zuo, “Multi-Substrate Selectivity Based on Key Loops and Non-Homologous Domains: New Insight Into ALKBH Family,” Cellular and Molecular Life Sciences 78, no. 1 (2021): 129–141.

[74] P. Wang, J. Wu, S. Ma, et al., “Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents,” Cell Reports 13, no. 11 (2015): 2353–2361.

[75] K. Tateishi, H. Wakimoto, A. J. Iafrate, et al., “Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion,” Cancer Cell 28, no. 6 (2015): 773–784.

[76] Y.-Y.-F. Feng, Y.-C. Li, H.-M. Liu, et al., “Synthetic Lethal CRISPR Screen Identifies a Cancer Cell-Intrinsic Role of PD-L1 in Regulation of Vulnerability to Ferroptosis,” Cell Reports 43, no. 7 (2024): 114477.

[77] M. Wang, X. Ran, W. Leung, et al., “ATR Inhibition Induces Synthetic Lethality in Mismatch Repair-Deficient Cells and Augments Immunotherapy,” Genes & Development 37, no. 19–20 (2023): 929–943.

[78] C. Liang, M. Ye, L. Yu, et al., “Lysine-Specific Demethylase 1 Deletion Reshapes Tumour Microenvironment to Overcome Acquired Resistance to Anti-Programmed Death 1 Therapy in Liver Cancer,” Clinical and Translational Medicine 15, no. 5 (2025): e70335.

[79] J. H. Sussman, J. Xu, N. Amankulor, and K. Tan, “Dissecting the Tumor Microenvironment of Epigenetically Driven Gliomas: Opportunities for Single-Cell and Spatial Multiomics,” Neuro-Oncology Advances 5, no. 1 (2023): vdad101.

[80] P. Gupta, M. Dang, S. Oberai, et al., “Immune Landscape of Isocitrate Dehydrogenase-Stratified Primary and Recurrent Human Gliomas,” Neuro-Oncology 26, no. 12 (2024): 2239–2255.

[81] A. Sarantopoulos, C. Ene, and E. Aquilanti, “Therapeutic Approaches to Modulate the Immune Microenvironment in Gliomas,” NPJ Precision Oncology 8, no. 1 (2024): 241.

[82] Y. N. Lamb, “Vorasidenib: First Approval,” Drugs 84, no. 10 (2024): 1325–1331.

[83] L. Zhang, M. D. Sorensen, B. W. Kristensen, G. Reifenberger, T. M. Mcintyre, and F. Lin, “D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells,” Clinical Cancer Research 24, no. 21 (2018): 5381–5391.

[84] L. Galluzzi and G. Kroemer, “Potent Immunosuppressive Effects of the Oncometabolite R-2-Hydroxyglutarate,” Oncoimmunology 7, no. 12 (2018): e1528815.

[85] G. Kohanbash, D. A. Carrera, S. Shrivastav, et al., “Isocitrate Dehydrogenase Mutations Suppress STAT1 and CD8+ T Cell Accumulation in Gliomas,” Journal of Clinical Investigation 127, no. 4 (2017): 1425–1437.

[86] L. G. Richardson, L. T. Nieman, A. O. Stemmer-Rachamimov, et al., “IDH-Mutant Gliomas Harbor Fewer Regulatory T Cells in Humans and Mice,” Oncoimmunology 9, no. 1 (2020): 1806662.

[87] X. Zhang, A. Rao, P. Sette, et al., “IDH Mutant Gliomas Escape Natural Killer Cell Immune Surveillance by Downregulation of NKG2D Ligand Expression,” Neuro-Oncology 18, no. 10 (2016): 1402–1412.

[88] X. Zhang, W. J. Kim, A. V. Rao, et al., “In Vivo Efficacy of Decitabine as a Natural Killer Cell-Mediated Immunotherapy Against Isocitrate Dehydrogenase Mutant Gliomas,” Neurosurgical Focus 52, no. 2 (2022): E3.

[89] M. Friedrich, M. Hahn, J. Michel, et al., “Dysfunctional Dendritic Cells Limit Antigen-Specific T Cell Response in Glioma,” Neuro-Oncology 25, no. 2 (2023): 263–276.

[90] N. M. Amankulor, Y. Kim, S. Arora, et al., “Mutant IDH1 Regulates the Tumor-Associated Immune System in Gliomas,” Genes & Development 31, no. 8 (2017): 774–786.

[91] X. Ran, J. Zheng, L. Chen, et al., “Single-Cell Transcriptomics Reveals the Heterogeneity of the Immune Landscape of IDH-Wild-Type High-Grade Gliomas,” Cancer Immunology Research 12, no. 2 (2024): 232–246.

[92] A. S. Berghoff, B. Kiesel, G. Widhalm, et al., “Correlation of Immune Phenotype With IDH Mutation in Diffuse Glioma,” Neuro-Oncology 19, no. 11 (2017): 1460–1468.

[93] F. Wu, G.-Z. Li, H.-J. Liu, et al., “Molecular Subtyping Reveals Immune Alterations in IDH Wild-Type Lower-Grade Diffuse Glioma,” Journal of Pathology 251, no. 3 (2020): 272–283.

[94] J. Tang, W. Fan, Y. Ruan, et al., “Protein-Based Classification Reveals an Immune-Hot Subtype in IDH Mutant Astrocytoma With Worse Prognosis,” Cancer Cell 43 (2025): 2136–2155.e14.

[95] T. Schumacher, L. Bunse, S. Pusch, et al., “A Vaccine Targeting Mutant IDH1 Induces Antitumour Immunity,” Nature 512, no. 7514 (2014): 324–327.

[96] S. Zhou, F. Ma, J. Gong, et al., “Immuno-Initiator Rectifies Immunodeficiency to Restore Immune Function and Potentiate Immunotherapy Against IDH Mutant Glioma,” ACS Nano 19, no. 29 (2025): 26980–27004.

[97] X. Si, M. Shao, X. Teng, et al., “Mitochondrial Isocitrate Dehydrogenase Impedes CAR T Cell Function by Restraining Antioxidant Metabolism and Histone Acetylation,” Cell Metabolism 36, no. 1 (2024): 176–192.e10.

[98] S. Hadad, R. Gupta, N. A. Oberheim Bush, et al., ““De Novo Replication Repair Deficient Glioblastoma, IDH-Wildtype” Is a Distinct Glioblastoma Subtype in Adults That May Benefit From Immune Checkpoint Blockade,” Acta Neuropathologica 147, no. 1 (2023): 3.

[99] J. J. D. Moffet, O. E. Fatunla, L. Freytag, et al., “Spatial Architecture of High-Grade Glioma Reveals Tumor Heterogeneity Within Distinct Domains,” Neuro-Oncology Advances 5, no. 1 (2023): vdad142.

[100] M. Liu, Z. Ji, V. Jain, et al., “Spatial Transcriptomics Reveals Segregation of Tumor Cell States in Glioblastoma and Marked Immunosuppression Within the Perinecrotic Niche,” Acta Neuropathologica Communications 12, no. 1 (2024): 64.

[101] Y. Yang, Y. Hong, K. Zhao, et al., “Spatial Transcriptomics Analysis Identifies Therapeutic Targets in Diffuse High-Grade Gliomas,” Frontiers in Molecular Neuroscience 17 (2024): 1466302.

[102] W. Chen, M. Zheng, J.-Y. An, et al., “Single-Cell and Spatial Transcriptome Sequencing Analysis Reveals Characteristics of a Unique Subpopulation in High-Grade IDH-Mutant Astrocytoma,” Cellular Oncology 49, no. 1 (2025): 8.

[103] X. Wang, J. Gu, H. Tang, et al., “Single-Cell Profiling and Proteomics-Based Insights Into mTORC1-Mediated Angio+TAMs Polarization in Recurrent IDH-Mutant Gliomas,” CNS Neuroscience & Therapeutics 31, no. 4 (2025): e70371.

[104] C. Jackson, C. Cherry, S. Bom, et al., “Distinct Myeloid-Derived Suppressor Cell Populations in Human Glioblastoma,” Science 387, no. 6731 (2025): eabm5214.

[105] J. Li, S. Long, Z. Yang, et al., “Single-Cell Transcriptomics Reveals IRF7 Regulation of the Tumor Microenvironment in Isocitrate Dehydrogenase Wild-Type Glioma,” MedComm 5, no. 11 2024: e754.

[106] C. Hartmann, J. Meyer, J. Balss, et al., “Type and Frequency of IDH1 and IDH2 Mutations Are Related to Astrocytic and Oligodendroglial Differentiation and Age: A Study of 1,010 Diffuse Gliomas,” Acta Neuropathologica 118, no. 4 (2009): 469–474.

[107] K. Ichimura, D. M. Pearson, S. Kocialkowski, et al., “IDH1 Mutations Are Present in the Majority of Common Adult Gliomas but Rare in Primary Glioblastomas,” Neuro-Oncology 11, no. 4 (2009): 341–347.

[108] J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. Von Deimling, “Analysis of the IDH1 Codon 132 Mutation in Brain Tumors,” Acta Neuropathologica 116, no. 6 (2008): 597–602.

[109] S. Xu, L. Cao, R. Chen, et al., “Differential Isocitrate Dehydrogenase 1 and Isocitrate Dehydrogenase 2 Mutation-Related Landscape in Intrahepatic Cholangiocarcinoma,” Oncologist 29, no. 8 (2024): e1061–e1072.

[110] V. Y. Jo, N. G. Chau, J. L. Hornick, J. F. Krane, and L. M. Sholl, “Recurrent IDH2 R172X Mutations in Sinonasal Undifferentiated Carcinoma,” Modern Pathology 30, no. 5 (2017): 650–659.

[111] J. K. Mito, J. A. Bishop, P. M. Sadow, et al., “Immunohistochemical Detection and Molecular Characterization of IDH-Mutant Sinonasal Undifferentiated Carcinomas,” American Journal of Surgical Pathology 42, no. 8 (2018): 1067–1075.

[112] S. Dogan, V. Vasudevaraja, B. Xu, et al., “DNA Methylation-Based Classification of Sinonasal Undifferentiated Carcinoma,” Modern Pathology 32, no. 10 (2019): 1447–1459.

[113] H. Yang, D. Ye, K.-L. Guan, and Y. Xiong, “IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives,” Clinical Cancer Research 18, no. 20 (2012): 5562–5571.

[114] R. A. Cairns, J. Iqbal, F. Lemonnier, et al., “IDH2 Mutations Are Frequent in Angioimmunoblastic T-Cell Lymphoma,” Blood 119, no. 8 (2012): 1901–1903.

[115] C. Wang, T. W. Mckeithan, Q. Gong, et al., “IDH2R172 Mutations Define a Unique Subgroup of Patients With Angioimmunoblastic T-Cell Lymphoma,” Blood 126, no. 15 (2015): 1741–1752.

[116] B. Samueli, H. Al-Ahmadie, Y.-B. Chen, et al., “Histopathologic and Molecular Characterization of IDH-Mutant Prostatic Adenocarcinoma,” Modern Pathology 38, no. 1 (2025): 100616.

[117] B. H. Wang, Y. H. Li, and L. Yu, “Genomics-Based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-Risk Acute Myeloid Leukemia,” Chinese Medical Journal 128, no. 17 (2015): 2395–2403.

[118] D. Kunadt, S. Stasik, K. H. Metzeler, et al., “Impact of IDH1 and IDH2 Mutational Subgroups in AML Patients After Allogeneic Stem Cell Transplantation,” Journal of Hematology & Oncology 15, no. 1 (2022): 126.

[119] Q. Xu, Y. Li, N. Lv, et al., “Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis,” Clinical Cancer Research 23, no. 15 (2017): 4511–4522.

[120] C. A. Lachowiez, P. K. Reville, H. Kantarjian, et al., “Contemporary Outcomes in IDH-Mutated Acute Myeloid Leukemia: The Impact of Co-Occurring NPM1 Mutations and Venetoclax-Based Treatment,” American Journal of Hematology 97, no. 11 (2022): 1443–1452.

[121] Y. Qin, K. Shen, T. Liu, and H. Ma, “Prognostic Value of IDH2R140 and IDH2R172 Mutations in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis,” BMC Cancer 23, no. 1 (2023): 527.

[122] R. Rudà, C. Horbinski, M. Van Den Bent, M. Preusser, and R. Soffietti, “IDH Inhibition in Gliomas: From Preclinical Models to Clinical Trials,” Nature Reviews Neurology 20, no. 7 (2024): 395–407.

[123] J. Popovici-Muller, R. M. Lemieux, E. Artin, et al., “Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers,” ACS Medicinal Chemistry Letters 9, no. 4 (2018): 300–305.

[124] A. Chaturvedi, L. Herbst, S. Pusch, et al., “Pan-Mutant-IDH1 Inhibitor BAY1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo,” Leukemia 31, no. 10 (2017): 2020–2028.

[125] V. Rey, J. Tornín, J. J. Alba-Linares, et al., “A Personalized Medicine Approach Identifies Enasidenib as an Efficient Treatment for IDH2 Mutant Chondrosarcoma,” EBioMedicine 102 (2024): 105090.

[126] Y. Machida, M. Nakagawa, H. Matsunaga, et al., “A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma With IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model,” Molecular Cancer Therapeutics 19, no. 2 (2020): 375–383.

[127] Z. Konteatis, E. Artin, B. Nicolay, et al., “Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma,” ACS Medicinal Chemistry Letters 11, no. 2 (2020): 101–107.

[128] Y. S. Cho, J. R. Levell, G. Liu, et al., “Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor,” ACS Medicinal Chemistry Letters 8, no. 10 (2017): 1116–1121.

[129] A. Chaturvedi, C. Gupta, R. Gabdoulline, et al., “Synergistic Activity of IDH1 Inhibitor BAY1436032 With Azacitidine in IDH1 Mutant Acute Myeloid Leukemia,” Haematologica 106, no. 2 (2021): 565–573.

[130] M. Nakagawa, F. Nakatani, H. Matsunaga, et al., “Selective Inhibition of Mutant IDH1 by DS-1001b Ameliorates Aberrant Histone Modifications and Impairs Tumor Activity in Chondrosarcoma,” Oncogene 38, no. 42 (2019): 6835–6849.

[131] S. Dhillon, “Ivosidenib: First Global Approval,” Drugs 78, no. 14 (2018): 1509–1516.

[132] P. L. S. Uson Junior and M. J. Borad, “Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence to Date,” Cancer Management and Research 15 (2023): 1025–1031.

[133] A. C. Woods, E. D. Pulte, X. Wang, et al., “FDA Approval Summary: Ivosidenib for Treatment of Adult Patients With Relapsed/Refractory Myelodysplastic Syndrome With an IDH1 Mutation,” Clinical Cancer Research 31, no. 17 (2025): 3613–3617.

[134] G. J. Roboz, C. D. Dinardo, E. M. Stein, et al., “Ivosidenib Induces Deep Durable Remissions in Patients With Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia,” Blood 135, no. 7 (2020): 463–471.

[135] C. D. Dinardo, E. M. Stein, S. De Botton, et al., “Durable Remissions With Ivosidenib in IDH1-Mutated Relapsed or Refractory AML,” New England Journal of Medicine 378, no. 25 (2018): 2386–2398.

[136] E. M. Stein, C. D. Dinardo, A. T. Fathi, et al., “Ivosidenib or Enasidenib Combined With Intensive Chemotherapy in Patients With Newly Diagnosed AML: A Phase 1 Study,” Blood 137, no. 13 (2021): 1792–1803.

[137] G. K. Abou-Alfa, T. Macarulla, M. M. Javle, et al., “Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study,” Lancet Oncology 21, no. 6 (2020): 796–807.

[138] A. X. Zhu, T. Macarulla, M. M. Javle, et al., “Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial,” JAMA Oncology 7, no. 11 (2021): 1669.

[139] I. K. Mellinghoff, B. M. Ellingson, M. Touat, et al., “Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma,” Journal of Clinical Oncology 38, no. 29 (2020): 3398–3406.

[140] S. R. Frankel, A. Eardley, G. Lauwers, M. Weiss, and R. P. Warrell, “The “Retinoic Acid Syndrome” in Acute Promyelocytic Leukemia,” Annals of Internal Medicine 117, no. 4 (1992): 292–296.

[141] A. T. Fathi, C. D. Dinardo, I. Kline, et al., “Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study,” JAMA Oncology 4, no. 8 (2018): 1106.

[142] B. Fan, G. K. Abou-Alfa, A. X. Zhu, et al., “Pharmacokinetics/Pharmacodynamics of Ivosidenib in Advanced IDH1-Mutant Cholangiocarcinoma: Findings From the Phase III ClarIDHy Study,” Cancer Chemotherapy and Pharmacology 93, no. 5 (2024): 471–479.

[143] J. A. Caravella, J. Lin, R. B. Diebold, et al., “Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor,” Journal of Medicinal Chemistry 63, no. 4 (2020): 1612–1623.

[144] R. Reinbold, I. C. Hvinden, P. Rabe, et al., “Resistance to the Isocitrate Dehydrogenase 1 Mutant Inhibitor Ivosidenib Can be Overcome by Alternative Dimer-Interface Binding Inhibitors,” Nature Communications 13, no. 1 (2022): 4785.

[145] S. De Botton, P. Fenaux, K. Yee, et al., “Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients With Relapsed or Refractory IDH1-Mutated AML,” Blood Advances 7, no. 13 (2023): 3117–3127.

[146] M. Heuser, N. Palmisiano, I. Mantzaris, et al., “Safety and Efficacy of BAY1436032 in IDH1-Mutant AML: Phase I Study Results,” Leukemia 34, no. 11 (2020): 2903–2913.

[147] A. Wick, O. Bähr, M. Schuler, et al., “Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients With IDH1-Mutant Solid Tumors,” Clinical Cancer Research 27, no. 10 (2021): 2723–2733.

[148] A. Natsume, Y. Arakawa, Y. Narita, et al., “The First-in-Human Phase I Study of a Brain-Penetrant Mutant IDH1 Inhibitor DS-1001 in Patients With Recurrent or Progressive IDH1-Mutant Gliomas,” Neuro-Oncology 25, no. 2 (2023): 326–336.

[149] C. D. Dinardo, A. Hochhaus, M. G. Frattini, et al., “A Phase 1 Study of IDH305 in Patients With IDH1(R132)-Mutant Acute Myeloid Leukemia or Myelodysplastic Syndrome,” Journal of Cancer Research and Clinical Oncology 149, no. 3 (2023): 1145–1158.

[150] E. M. Stein, A. T. Fathi, C. D. Dinardo, et al., “Enasidenib in Patients With Mutant IDH2 Myelodysplastic Syndromes: A Phase 1 Subgroup Analysis of the Multicentre, AG221-C-001 Trial,” Lancet Haematology 7, no. 4 (2020): e309–e319.

[151] E. M. Stein, C. D. Dinardo, A. T. Fathi, et al., “Molecular Remission and Response Patterns in Patients With Mutant-IDH2 Acute Myeloid Leukemia Treated With Enasidenib,” Blood 133, no. 7 (2019): 676–687.

[152] S. De Botton, P. Montesinos, A. C. Schuh, et al., “Enasidenib vs Conventional Care in Older Patients With Late-Stage Mutant-IDH2 Relapsed/Refractory AML: A Randomized Phase 3 Trial,” Blood 141, no. 2 (2023): 156–167.

[153] I. K. Mellinghoff, M. J. Van Den Bent, D. T. Blumenthal, et al., “Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma,” New England Journal of Medicine 389, no. 7 (2023): 589–601.

[154] C. D. Dinardo, S. De Botton, D. A. Pollyea, et al., “Safety, Efficacy, and PK/PD of Vorasidenib in Previously Treated Patients With mIDH1/2 Hematologic Malignancies: A Phase 1 Study,” American Journal of Hematology 98, no. 9 (2023): E233–E236.

[155] M. D. Lin, A. C.-Y. Tsai, K. G. Abdullah, S. K. Mcbrayer, and D. D. Shi, “Treatment of IDH-Mutant Glioma in the INDIGO Era,” NPJ Precision Oncology 8, no. 1 (2024): 149.

[156] K. Xiao, Z. Zhang, Y. Wu, et al., “Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment,” ACS Medicinal Chemistry Letters 16, no. 3 (2025): 454–463.

[157] T. M. Getz and J. P. Bewersdorf, “More Than Just Another IDH Inhibitor: Insights From the HMPL-306 Phase 1 Trial,” Med 6, no. 6 (2025): 100600.

[158] J. M. Watts, M. R. Baer, J. Yang, et al., “Olutasidenib Alone or With Azacitidine in IDH1-Mutated Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Phase 1 Results of a Phase 1/2 Trial,” Lancet Haematology 10, no. 1 (2023): e46–e58.

[159] X. Zhuang, H. Z. Pei, T. Li, et al., “The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia,” Frontiers in Oncology 12 (2022): 931462.

[160] I. K. Mellinghoff, M. Penas-Prado, K. B. Peters, et al., “Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial,” Clinical Cancer Research 27, no. 16 (2021): 4491–4499.

[161] T. Wang, A. R. Pine, A. G. Kotini, et al., “Sequential CRISPR Gene Editing in Human iPSCs Charts the Clonal Evolution of Myeloid Leukemia and Identifies Early Disease Targets,” Cell Stem Cell 28, no. 6 (2021): 1074–1089.e7.

[162] K. Morita, F. Wang, K. Jahn, et al., “Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics,” Nature Communications 11, no. 1 (2020): 5327.

[163] L. Quek, M. D. David, A. Kennedy, et al., “Clonal Heterogeneity of Acute Myeloid Leukemia Treated With the IDH2 Inhibitor Enasidenib,” Nature Medicine 24, no. 8 (2018): 1167–1177.

[164] S. Avanzini and T. Antal, “Cancer Recurrence Times From a Branching Process Model,” PLOS Computational Biology 15, no. 11 (2019): e1007423.

[165] N. D. Lee and I. Bozic, “Inferring Parameters of Cancer Evolution in Chronic Lymphocytic Leukemia,” PLOS Computational Biology 18, no. 11 (2022): e1010677.

[166] C. D. McFarland, L. A. Mirny, and K. S. Korolev, “Tug-of-War Between Driver and Passenger Mutations in Cancer and Other Adaptive Processes,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 42 (2014): 15138–15143.

[167] A. Li, D. Kibby, and J. Foo, “A Comparison of Mutation and Amplification-Driven Resistance Mechanisms and Their Impacts on Tumor Recurrence,” preprint, ArXiv, August 21 2023.

[168] F. Wang, K. Morita, C. D. Dinardo, et al., “Leukemia Stemness and Co-Occurring Mutations Drive Resistance to IDH Inhibitors in Acute Myeloid Leukemia,” Nature Communications 12, no. 1 (2021): 2607.

[169] P. Stelmach and A. Trumpp, “Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia,” Haematologica 108, no. 2 (2023): 353–366.

[170] L. de Beauchamp, E. Himonas, and G. V. Helgason, “Mitochondrial Metabolism as a Potential Therapeutic Target in Myeloid Leukaemia,” Leukemia 36, no. 1 (2022): 1–12.

[171] X.-H. Liang, X.-Y. Chen, Y. Yan, et al., “Targeting Metabolism to Enhance Immunotherapy Within Tumor Microenvironment,” Acta Pharmacologica Sinica 45, no. 10 (2024): 2011–2022.

[172] C. Fan, S. Zhang, Z. Gong, et al., “Emerging Role of Metabolic Reprogramming in Tumor Immune Evasion and Immunotherapy,” Science China Life Sciences 64, no. 4 (2021): 534–547.

[173] A. Gieryng, D. Pszczolkowska, K. A. Walentynowicz, W. D. Rajan, and B. Kaminska, “Immune Microenvironment of Gliomas,” Laboratory Investigation 97, no. 5 (2017): 498–518.

[174] T. Cui, L. Sun, X. Guo, et al., “Corrigendum to ‘Tumor-Derived CD109 Orchestrates Reprogramming of Tumor-Associated Macrophages to Dampen Immune Response’ (J Hepatol 2025 [946-958]),” Journal of Hepatology 84, no. 1 (2026): 238.

[175] E. Loeuillard, J. Yang, E. Buckarma, et al., “Targeting Tumor-Associated Macrophages and Granulocytic Myeloid-Derived Suppressor Cells Augments PD-1 Blockade in Cholangiocarcinoma,” Journal of Clinical Investigation 130, no. 10 (2020): 5380–5396.

[176] J. E. Bader, K. Voss, and J. C. Rathmell, “Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy,” Molecular Cell 78, no. 6 (2020): 1019–1033.

[177] E. P. Grewal, L. G. K. Richardson, J. Sun, et al., “Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma,” Clinical Cancer Research 30, no. 18 (2024): 4068–4076.

[178] Q. Lei, D. Wang, K. Sun, L. Wang, and Y. Zhang, “Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors,” Frontiers in Cell and Developmental Biology 8 (2020): 672.

[179] S. Koyama, E. A. Akbay, Y. Y. Li, et al., “Adaptive Resistance to Therapeutic PD-1 Blockade Is Associated With Upregulation of Alternative Immune Checkpoints,” Nature Communications 7 (2016): 10501.

[180] D. B. Johnson, M. V. Estrada, R. Salgado, et al., “Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-PD-1/PD-L1 Therapy,” Nature Communications 7 (2016): 10582.

[181] M.-J. Wu, L. Shi, J. Dubrot, et al., “Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma,” Cancer Discovery 12, no. 3 (2022): 812–835.

[182] Y. Sun, L. Maggs, A. Panda, et al., “TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids,” Cancer Immunology Research 13, no. 2 (2025): 210–228.

[183] G. Jin, Z. J. Reitman, I. Spasojevic, et al., “2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP-Dependent Isocitrate Dehydrogenase Mutations,” PLoS One 6, no. 2 (2011): e16812.

[184] P. L. Sulkowski, S. Oeck, J. Dow, et al., “Oncometabolites Suppress DNA Repair by Disrupting Local Chromatin Signalling,” Nature 582, no. 7813 (2020): 586–591.

[185] C. D. Dinardo, B. A. Jonas, V. Pullarkat, et al., “Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia,” New England Journal of Medicine 383, no. 7 (2020): 617–629.

[186] A. H. Shih, C. Meydan, K. Shank, et al., “Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia,” Cancer Discovery 7, no. 5 (2017): 494–505.

[187] P. Montesinos, D. M. Marchione, C. Recher, et al., “Long-Term Results From the AGILE Study of Azacitidine Plus Ivosidenib vs Placebo in Newly Diagnosed IDH1-Mutated AML,” Blood Advances 9, no. 20 (2025): 5177–5189.

[188] S. F. Cai, Y. Huang, J. R. Lance, et al., “A Study to Assess the Efficacy of Enasidenib and Risk-Adapted Addition of Azacitidine in Newly Diagnosed IDH2-Mutant AML,” Blood Advances 8, no. 2 (2024): 429–440.

[189] S. Venugopal, K. Takahashi, N. Daver, et al., “Efficacy and Safety of Enasidenib and Azacitidine Combination in Patients With IDH2 Mutated Acute Myeloid Leukemia and Not Eligible for Intensive Chemotherapy,” Blood Cancer Journal 12, no. 1 (2022): 10.

[190] C. D. Dinardo, J. Marvin-Peek, S. Loghavi, et al., “Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML,” Journal of Clinical Oncology 43, no. 24 (2025): 2692–2699.

[191] Y. Kim, H.-K. Jeung, J.-W. Cheong, et al., “All-Trans Retinoic Acid Synergizes With Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells,” Yonsei Medical Journal 61, no. 9 (2020): 762.

[192] Y. Wang, A. T. Wild, S. Turcan, et al., “Targeting Therapeutic Vulnerabilities With PARP Inhibition and Radiation in IDH-Mutant Gliomas and Cholangiocarcinomas,” Science Advances 6, no. 17 (2020): eaaz3221.

[193] I. K. Mellinghoff, M. Lu, P. Y. Wen, et al., “Vorasidenib and Ivosidenib in IDH1-Mutant Low-Grade Glioma: A Randomized, Perioperative Phase 1 Trial,” Nature Medicine 29, no. 3 (2023): 615–622.

[194] M.-J. Wu, H. Kondo, A. V. Kammula, et al., “Mutant IDH1 Inhibition Induces dsDNA Sensing to Activate Tumor Immunity,” Science 385, no. 6705 (2024): eadl6173.

[195] M. Platten, L. Bunse, A. Wick, et al., “A Vaccine Targeting Mutant IDH1 in Newly Diagnosed Glioma,” Nature 592, no. 7854 (2021): 463–468.

[196] S. Pellegatta, L. Valletta, C. Corbetta, et al., “Effective Immuno-Targeting of the IDH1 Mutation R132H in a Murine Model of Intracranial Glioma,” Acta Neuropathologica Communications 3 (2015): 4.

[197] M. Platten, L. Bunse, and W. Wick, “Emerging Targets for Anticancer Vaccination: IDH,” ESMO Open 6, no. 4 (2021): 100214.

[198] W. B. Pope, R. M. Prins, M. Albert Thomas, et al., “Non-Invasive Detection of 2-Hydroxyglutarate and Other Metabolites in IDH1 Mutant Glioma Patients Using Magnetic Resonance Spectroscopy,” Journal of Neuro-Oncology 107, no. 1 (2012): 197–205.

[199] O. C. Andronesi, G. S. Kim, E. Gerstner, et al., “Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy,” Science Translational Medicine 4, no. 116 (2012): 116ra4.

[200] C. Choi, J. M. Raisanen, S. K. Ganji, et al., “Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma,” Journal of Clinical Oncology 34, no. 33 (2016): 4030–4039.

[201] H. Nagashima, K. Tanaka, T. Sasayama, et al., “Diagnostic Value of Glutamate With 2-Hydroxyglutarate in Magnetic Resonance Spectroscopy for IDH1 Mutant Glioma,” Neuro-Oncology 18, no. 11 (2016): 1559–1568.

[202] C. L. Lee, G. M. O'Kane, W. P. Mason, et al., “Circulating Oncometabolite 2-Hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma,” Molecular Cancer Therapeutics 23, no. 3 (2024): 394–399.

[203] G. Lombardi, G. Corona, L. Bellu, et al., “Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma,” Oncologist 20, no. 5 (2015): 562–567.

[204] A. T. Fathi, B. V. Nahed, S. A. Wander, et al., “Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma,” Oncologist 21, no. 2 (2016): 214–219.

[205] E. Fernández-Galán, N. Massana, M. Parra-Robert, et al., “Validation of a Routine Gas Chromatography Mass Spectrometry Method for 2-Hydroxyglutarate Quantification in Human Serum as a Screening Tool for Detection of Idh Mutations,” Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 1083 (2018): 28–34.

[206] C. Riviere-Cazaux, J. M. Lacey, L. P. Carlstrom, et al., “Cerebrospinal Fluid 2-Hydroxyglutarate as a Monitoring Biomarker for IDH-Mutant Gliomas,” Neuro-Oncology Advances 5, no. 1 (2023): vdad061.

[207] Y. Fujita, L. Nunez-Rubiano, A. Dono, et al., “IDH1 p.R132H ctDNA and D-2-Hydroxyglutarate as CSF Biomarkers in Patients With IDH-Mutant Gliomas,” Journal of Neuro-Oncology 159, no. 2 (2022): 261–270.

[208] J. Kalinina, J. Ahn, N. S. Devi, et al., “Selective Detection of the D-Enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients With Mutated Isocitrate Dehydrogenase,” Clinical Cancer Research 22, no. 24 (2016): 6256–6265.

[209] O. C. Andronesi, I. C. Arrillaga-Romany, K. I. Ly, et al., “Pharmacodynamics of Mutant-IDH1 Inhibitors in Glioma Patients Probed by In Vivo 3D MRS Imaging of 2-Hydroxyglutarate,” Nature Communications 9, no. 1 (2018): 1474.

[210] A. R. Molloy, C. Najac, P. Viswanath, et al., “MR-Detectable Metabolic Biomarkers of Response to Mutant IDH Inhibition in Low-Grade Glioma,” Theranostics 10, no. 19 (2020): 8757–8770.

[211] G. Batsios, P. Viswanath, E. Subramani, et al., “PI3K/mTOR Inhibition of IDH1 Mutant Glioma Leads to Reduced 2HG Production That Is Associated With Increased Survival,” Scientific Reports 9, no. 1 (2019): 10521.

[212] O. C. Andronesi, F. Loebel, W. Bogner, et al., “Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate,” Clinical Cancer Research 22, no. 7 (2016): 1632–1641.

[213] E. Subramani, M. Radoul, C. Najac, et al., “Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment,” Cancer Research 80, no. 22 (2020): 5098–5108.

[214] C. Trautwein, L. Zizmare, I. Mäurer, et al., “Tissue Metabolites in Diffuse Glioma and Their Modulations by IDH1 Mutation, Histology, and Treatment,” JCI Insight 7, no. 3 (2022): e153526.

[215] F. Fack, S. Tardito, G. Hochart, et al., “Altered Metabolic Landscape in IDH-Mutant Gliomas Affects Phospholipid, Energy, and Oxidative Stress Pathways,” EMBO Molecular Medicine 9, no. 12 (2017): 1681–1695.

[216] L. E. Jalbert, A. Elkhaled, J. J. Phillips, et al., “Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma,” Scientific Reports 7 (2017): 44792.

[217] S. Pathmanapan, O. Ilkayeva, J. T. Martin, et al., “Mutant IDH and Non-Mutant Chondrosarcomas Display Distinct Cellular Metabolomes,” Cancer & Metabolism 9, no. 1 (2021): 13.

[218] Z. J. Reitman, G. Jin, E. D. Karoly, et al., “Profiling the Effects of Isocitrate Dehydrogenase 1 and 2 Mutations on the Cellular Metabolome,” Proceedings of the National Academy of Sciences of the United States of America 108, no. 8 (2011): 3270–3275.

[219] O. C. Andronesi, O. Rapalino, E. Gerstner, et al., “Detection of Oncogenic IDH1 Mutations Using Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate,” Journal of Clinical Investigation 123, no. 9 (2013): 3659–3663.

[220] U. E. Emir, S. J. Larkin, N. De Pennington, et al., “Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas With IDH1 and IDH2 Mutations,” Cancer Research 76, no. 1 (2016): 43–49.

[221] E. Gruber, J. So, A. C. Lewis, et al., “Inhibition of Mutant IDH1 Promotes Cycling of Acute Myeloid Leukemia Stem Cells,” Cell Reports 40, no. 7 (2022): 111182.

[222] A. C. Greenwald, N. G. Darnell, R. Hoefflin, et al., “Integrative Spatial Analysis Reveals a Multi-Layered Organization of Glioblastoma,” Cell 187, no. 10 (2024): 2485–2501.e26.

[223] M. Motevasseli, M. Darvishi, A. Khoshnevisan, et al., “Distinct Tumor-TAM Interactions in IDH-Stratified Glioma Microenvironments Unveiled by Single-Cell and Spatial Transcriptomics,” Acta Neuropathologica Communications 12, no. 1 (2024): 133.

[224] F. Lordick, F. Carneiro, S. Cascinu, et al., “Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up,” Annals of Oncology 33, no. 10 (2022): 1005–1020.

[225] G. Richard-Carpentier, G. Gupta, C. Koraksic, et al., “Enasidenib Plus Venetoclax in Patients With IDH2-Mutated Relapsed or Refractory Acute Myeloid Leukaemia or Myelodysplastic Syndrome (ENAVEN-AML): A Multicentre, Single-Arm, Phase 1b/2 Trial,” Lancet Haematology 12, no. 11 (2025): e887–e897.

[226] M. K. Nguyen, M. Jelinek, A. Singh, et al., “Clinical and Translational Study of Ivosidenib Plus Nivolumab in Advanced Solid Tumors Harboring IDH1 Mutations,” preprint, medRxiv, July 21 2025.

[227] H. Fruchtman, Z. M. Avigan, J. A. Waksal, N. Brennan, and J. O. Mascarenhas, “Management of Isocitrate Dehydrogenase 1/2 Mutated Acute Myeloid Leukemia,” Leukemia 38, no. 5 (2024): 927–935.

[228] J. Di, T. Sheng, R. Arora, et al., “The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients With Acute Myeloid Leukemia,” Journal of Molecular Diagnostics 27, no. 2 (2025): 100–108.

[229] J. S. Blachly, R. B. Walter, and C. S. Hourigan, “The Present and Future of Measurable Residual Disease Testing in Acute Myeloid Leukemia,” Haematologica 107, no. 12 (2022): 2810–2822.

[230] S. Kishimoto, J. R. Brender, D. R. Crooks, et al., “Imaging of Glucose Metabolism by 13C-MRI Distinguishes Pancreatic Cancer Subtypes in Mice,” Elife 8 (2019): e46312.

[231] J. Lyu, Y. Liu, N. Liu, et al., “CD44-Mediated Metabolic Rewiring Is a Targetable Dependency of IDH-Mutant Leukemia,” Blood 145, no. 14 (2025): 1553–1567.

[232] S. Pan, K. Mirchia, E. Payne, et al., “Tumor Heterogeneity Underlies Clinical Outcome and MEK Inhibitor Response in Somatic NF1-Mutant Glioblastoma,” JCI Insight 10, no. 18 (2025): e192658.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.